MPN-164 Outcomes With Allogeneic Hematopoietic Stem Cell Transplantation INTP53-Mutated Myeloproliferative Neoplasms: A Systematic Review Andmeta-Analysis

• Published in: Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2024-09, Vol.24, p.S419-S420
• Main Authors: Shahzad, Moazzam, Noor, Jawad, Fareed Khalid, Muhammad, Mujtaba, Ghulam, Jaglal, Michael
• Format: Article
• Language: English
• Subjects: allogeneic hematopoietic stem cell transplantation; MPN; systematic review
• ISSN: 2152-2650
• DOI: 10.1016/S2152-2650(24)01408-3

Allogeneic hematopoietic stem cell transplantation (allo-HCT) is crucial for patients with myeloproliferative neoplasms (MPN). However, data on its efficacy in MPN patients with the TP53 mutation is limited. This systematic review and meta-analysis examine the outcomes of allo-HCT in patients with TP53-mutated MPNs A comprehensive literature search was performed on 3 databases (PubMed, Cochrane Register of Controlled Trials, and Clinicaltrials.gov) using MeSH terms and the keywords ‘Myeloproliferative Disorders’ AND ‘TP53 gene’ AND ‘Allogeneic Transplantation’ from the date of inception to May 1, 2024. The search produced 24 articles. After primary and secondary screening, 3 studies were included. The interstudy variance was calculated by using the DerSimonian-Laird Estimator. Proportions, along with a 95% confidence interval (CI), were extracted to compute a pooled analysis in the ‘meta’ package by Schwarzer et al. in the R program. The 3 studies reporting the role of allo-HCT in TP53-mutated MPN, conducted from 2020 to 2022, included 117 patients. Median follow-up was 71.4 (range, 69.6-73.2) months. At 6 years of follow-up, the pooled overall survival (OS) was 30.8% (95% CI 0.08-0.48, I2=85%, P